ArticleNature communications2015

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.

Tina Gruosso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.